A Dark Vector Cognition product

Cover and table of contents

7K characters. Original on sec.gov ·

Cover and table of contents

The 5 tables in Cover and table of contents as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q/A

(Amendment No. 1)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026**, or**

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-17272

BIO-TECHNE CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota41-1427402
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
614 McKinley Place N.E. Minneapolis**,** MN 55413(612) 379-8854
(Address of principal executive offices) (Zip Code)(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueTECHThe NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b- 2). ☐ Yes ☒ No

At November 2, 2026, 157,090,727 shares of the Company's Common Stock (par value $0.01) were outstanding.

​

EXPLANATORY NOTE

Bio-Techne Corporate is filing this Amendment No. 1 on Form 10-Q/A (the “Amendment”) to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 6, 2026 (the “Original Report”), solely to correct the signature page to the Original Report, which inadvertently omitted the conformed electronic signatures.

Except for the adding of the conformed electronic signatures, no other changes have been made to the Original Report. This Amendment does not reflect any subsequent events occurring after the original filing date of the Original Report or modify or update in any way disclosures made in the Original Report.

​

​

​

​

​

​

TABLE OF CONTENTS

​

Page
PART I. FINANCIAL INFORMATION
Item 1.Condensed Consolidated Financial Statements (Unaudited)1
Condensed Consolidated Statements of Earnings and Comprehensive Income1
​Condensed Consolidated Balance Sheets2
​Condensed Consolidated Statements of Cash Flows3
​Condensed Consolidated Statements of Stockholders’ Equity4
​Notes to Condensed Consolidated Financial Statements5
​Note 1. Basis of Presentation and Summary of Significant Accounting Policies5
​Note 2. Revenue Recognition6
​Note 3. Selected Balance Sheet Information8
​Note 4. Fair Value Measurements9
​Note 5. Debt and Other Financing Arrangements12
​Note 6. Leases12
​Note 7. Supplemental Equity and Accumulated Other Comprehensive Income (Loss)14
​Note 8. Earnings Per Share15
​Note 9. Share-based Compensation and Other Benefit Plans15
​Note 10. Other Income/(Expense)16
​Note 11. Income Taxes16
​Note 12. Segment Information16
​Note 13. Restructuring17
​Note 14. Subsequent Events19
​​​
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations20
Item 3.Quantitative and Qualitative Disclosures about Market Risk27
Item 4.Controls and Procedures27
PART II: OTHER INFORMATION
Item 1.Legal Proceedings27
Item 1A.Risk Factors27
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds27
Item 3.Defaults Upon Senior Securities28
Item 4.Mine Safety Disclosures28
Item 5.Other Information28
Item 6.Exhibits29
​SIGNATURES30

​

​

​

​

​

​

PART I. FINANCIAL INFORMATION

Next: Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS